Classer les publications sur l'année

  • Économie de la santé

    Perioperative time and economic impact of an intracameral combination of mydriatics and anaesthetics in routine cataract surgery.

    ZALUSKI S, AMZALLAG T, BOUCHUT P, PINSARD L, THERON JP, TELLOUCK-MORINCOMME J, BAFFERT S.

    Eur J Ophthalmol ; 2023;33(1):239-246

  • Économie de la santé

    Modelling lifetime cost consequences of toric compared with standard IOLs in cataract surgery of astigmatic patients in four European countries

    LAURENDEAU C, LAFUMA A, BERDEAUX G

    J Med Economics ; 12(3):230-237

  • Économie de la santé

    Modelling the lifetime economic consequences of glaucoma in France

    PHILIPPE NORDMANN J, LAFUMA A, BERDEAUX G

    J Med Econ ; 12(1):9-16

  • Économie de la santé

    Modelling lifetimes cost consequences of RESTOR for presbyopia in four European countries

    LAFUMA A, BERDEAUX G

    Eye ; 23(5):1072-80

  • Pharmaco-Epidémiologie

    Les troubles musculosquelettiques en viticulture : prévalence et associations avec le travail de la vigne et les facteurs psychosociaux au travail

    BERNARD C, BOUÉE S, COUROUVE L, ADJEMIAN A, CHRETIEN JC, NIEDHAMMER I

    Arch Mal Prof Environ ; 70:539-549

  • Pharmaco-Epidémiologie

    Incidence of Nd : YAG laser capsulotomies after cataract surgery : comparison of 3 square-edged lenses of different composition

    BOUREAU C, LAFUMA A, JEANBAT V, BERDEAUX G, SMITH ANDREW F

    Can J Ophtalmol ; 44(2):165-170

  • Économie de la santé

    Economics and attitudes regarding spectacles in daily life : a European perspective

    Economics and attitudes regarding spectacles in daily life : a European perspective

    Ophthalmic Epidemiol ; 16(4):218-223

  • Économie de la santé

    Cost of cataract surgery after implantation of three intraocular lenses

    BOUREAU C, LAFUMA A, JEANBAT V, SMITH AF, BERDEAUX G

    Clin Ophtalmol ; 3:277-285

  • Économie de la santé

    Cost effectiveness of Travoprost versus a Fixed Combination of Latanoprost/Timolol in Patients with Ocular Hypertension or Glaucoma : Analysis Based on the UK General Practitioner Research DataBase

    DE NATALE R, LAFUMA A, BERDEAUX G

    Clin Drug Investig ; 29(2):111-120

  • Économie de la santé

    Modelling lifetimes cost consequences of RESTOR in cataract surgery in four European countries

    LAFUMA A, BERDEAUX G

    BMC Ophtalmol ; 8(1):12

  • Pharmaco-Epidémiologie

    Intraocular pressure control with latanoprost/timolol and travoprost/timolol fixed combinations : a retrospective, multicentre, cross-sectional study

    DENIS P, LAFUMA A, JEANBAT V, LAURENDEAU C, BERDEAUX G

    Clin Drug Investig ; 28(12):767-776

  • Pharmaco-Epidémiologie

    Intermediate visual acuity without spectacles following bilateral ReSTOR® implantation

    CUQ C, SPERA C, LAURENDEAU C, LAFUMA A, BERDEAUX G

    Eur J Ophtalmol ; 18(5):733-738

  • Économie de la santé

    Costs and persistence of carbonic anhydrase inhibitor versus alpha2 agonists, associated with beta-blockers, in glaucoma an ocular hypertension : an analysis of the UKGPRD database

    LAFUMA A, BERDEAUX G

    Curr Med Res Opin ; 24(5):1519-1527

  • Économie de la santé

    Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care : an analysis conducted on the UK General Practitioner Research Database

    LAFUMA A, LAURENDEAU C, BERDEAUX G

    J Med Econ ; 11(3):485-497

  • Économie de la santé

    Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by the United Kingdom General Practitioner Research Database

    DENIS P, LAFUMA A, BERDEAUX G

    Clin Ophtalmol ; 2(2):321-329